Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07523529 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Name: Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors — clinical trial record (NCT07523529)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SELECT-2CAR

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-target construct from a predefined target-pair library. The trial is designed to test whether biomarkerguided dual targeting can improve tumor control, reduce antigenescape risk, and preserve safety in solid tumors.

Trial Details

NCT Number	NCT07523529
Lead Sponsor	Beijing Biotech
Conditions	Advanced Unresectable, Metastatic
Enrollment	72 participants
Start Date	2026-03-02
Primary Completion	2027-04-14 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-04-13